Perspective: Multiplicity and Subgroups in the Context of Benefit–Risk Assessment
Statistics in Biopharmaceutical Research(2016)
Key words
Multiple comparisons,Multiple endpoints,Multiple testing,Regulatory agencies,Safety endpoints
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined